Adverse Drug Event Surveillance and Drug Withdrawals in the US from 1969 to 2002;One Hospital's ADR Summary Report for a Single Month (June 2005) – Preventable ADRs?;Mirtazapine-Induced Arthralgia and Coagulopathy;Cognitive Impairment with Aromatase Inhibitors?;TTP Associated with Quetiapine;Amiodarone and the Thyroid;NSAIDs and Acute Urinary Retention;Risks of Oral Anticoagulants Increase Sharply with Advanced Age
Restricted accessResearch articleFirst published online September, 2005
Adverse Drug Event Surveillance and Drug Withdrawals in the US from 1969 to 2002;One Hospital's ADR Summary Report for a Single Month (June 2005) – Preventable ADRs?;Mirtazapine-Induced Arthralgia and Coagulopathy;Cognitive Impairment with Aromatase Inhibitors?;TTP Associated with Quetiapine;Amiodarone and the Thyroid;NSAIDs and Acute Urinary Retention;Risks of Oral Anticoagulants Increase Sharply with Advanced Age
The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the FDA's medWatch program (800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers.
Get full access to this article
View all access options for this article.
References
1.
WysowskiD.K., SwartzL.Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002 - the importance of reporting suspected reactions.Arch Intern Med.2005; 165(12): 1363–1369.
2.
DemetM.M., MizrakS., Esen-DanaciA.Mirtazapine-induced arthralgia and coagulopathy – a case report.J Clin Psychopharmacol.2005; 25(4): 395–396.
3.
TralongoP., Di MariA., FerrauF.Cognitive impairment, aromatase inhibitors, and age.J Clin Oncol.2005; 23(19): 4243.
